Document is current
Any future updates will be listed below
-
Authors
Rendle, Katharine A. https://orcid.org/0000-0002-7761-8728
Ramogola-Masire, Doreen
Grover, Surbhi
,
Mathoma, Anikie
Montgomery, Anne
Ho-Foster, Ari
Monare, Barati
Saia, Chelsea
Ritzwoller, Debra
Ramontshonyane, Gaobakwe
Toneff, Hannah
Ramokate, Ireen
Kalman, Jillian
Wainwright, Jocelyn
Rendle, Katharine
Lefatshe, Katlego
Kesalopa, Koorileng
Linn, Kristin
Mokgopo, Lesedi
Bazzett-Matabele, Lisa
Mntande, Lydiah
Masilo, Maitumelo
Lekula, Oratile
Vuylsteke, Peter
Ketlametswe, Rebecca
Luckett, Rebecca
Beidas, Rinad S.
Kashamba, Thanolo
Song, Weilu
- License Information
-
More Information
Article History
Received: 14 August 2024
Accepted: 11 October 2024
First Online: 12 November 2024
Declarations
:
: This study has received ethics approval from the University of Pennsylvania on October 20, 2022, University of Botswana IRB on January 24, 2023, Republic of Botswana Ministry of Health on February 9, 2023, and Princess Marina Hospital (PMH) on May 10, 2023. Given the minimal risk of the study, we received a waiver of informed consent for trial participants. Interview participants will be consented directly prior to participation. The study is monitored by the Clinical Trials Scientific Review and Monitoring Committee at the University of Pennsylvania.
: Not applicable.
: KAR reports receiving grants from Pfizer and AstraZeneca paid to her institution, personal fees from Merck for serving as a scientific advisor, and honoraria and travel paid as an invited speaker from MJH Life Sciences, all outside the submitted work. DM reports honoraria paid as an invited speaker from MSD. SG reports personal fees from Lumonus, Harbinger Health, and Sustainable Dialogue for Peaceful Uses (SDPU) for serving as a scientific advisor, all outside the submitted work. RSB is a member of <i>Implementation Science Communications</i>. All views expressed are those of the authors and do not reflect the views of the National Cancer Institute or the Republic of Botswana.
